BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $399 | -55.7% | 5,862 | -46.8% | 0.01% | -28.6% |
| Q2 2023 | $900 | -16.2% | 11,021 | -23.9% | 0.01% | -41.7% |
| Q1 2023 | $1,074 | -39.8% | 14,482 | -32.7% | 0.01% | -45.5% |
| Q4 2022 | $1,785 | -99.9% | 21,533 | +340.7% | 0.02% | +29.4% |
| Q3 2022 | $1,388,000 | +10.3% | 4,886 | +34.7% | 0.02% | +30.8% |
| Q2 2022 | $1,258,000 | +270.0% | 3,628 | +362.2% | 0.01% | +550.0% |
| Q1 2022 | $340,000 | -36.9% | 785 | -24.7% | 0.00% | -33.3% |
| Q4 2021 | $539,000 | -88.8% | 1,042 | -89.5% | 0.00% | -86.4% |
| Q3 2021 | $4,792,000 | +22.1% | 9,889 | +13.4% | 0.02% | +22.2% |
| Q2 2021 | $3,925,000 | +4.8% | 8,717 | -11.1% | 0.02% | -10.0% |
| Q1 2021 | $3,745,000 | +5.5% | 9,805 | -12.3% | 0.02% | +5.3% |
| Q4 2020 | $3,551,000 | +195.2% | 11,184 | +130.2% | 0.02% | +137.5% |
| Q3 2020 | $1,203,000 | -62.2% | 4,858 | -59.7% | 0.01% | -69.2% |
| Q2 2020 | $3,183,000 | +847.3% | 12,053 | +580.2% | 0.03% | +766.7% |
| Q1 2020 | $336,000 | +12.4% | 1,772 | +30.0% | 0.00% | 0.0% |
| Q4 2019 | $299,000 | -12.3% | 1,363 | -21.9% | 0.00% | 0.0% |
| Q3 2019 | $341,000 | -73.9% | 1,745 | -72.1% | 0.00% | -66.7% |
| Q2 2019 | $1,305,000 | +133.0% | 6,258 | +121.9% | 0.01% | +80.0% |
| Q1 2019 | $560,000 | +21.2% | 2,820 | -11.7% | 0.01% | +25.0% |
| Q4 2018 | $462,000 | -69.6% | 3,193 | -57.2% | 0.00% | -63.6% |
| Q3 2018 | $1,521,000 | +71.3% | 7,452 | +24.2% | 0.01% | +37.5% |
| Q2 2018 | $888,000 | -27.3% | 6,001 | -25.8% | 0.01% | -20.0% |
| Q1 2018 | $1,222,000 | -31.2% | 8,090 | -41.0% | 0.01% | -41.2% |
| Q4 2017 | $1,775,000 | +37.8% | 13,703 | +25.0% | 0.02% | +41.7% |
| Q2 2017 | $1,288,000 | +76.7% | 10,962 | +52.9% | 0.01% | +100.0% |
| Q1 2017 | $729,000 | -28.5% | 7,171 | -27.7% | 0.01% | -33.3% |
| Q4 2016 | $1,019,000 | +237.4% | 9,913 | +259.4% | 0.01% | +200.0% |
| Q3 2016 | $302,000 | -82.0% | 2,758 | -81.5% | 0.00% | -75.0% |
| Q2 2016 | $1,682,000 | +23.4% | 14,912 | +3.4% | 0.01% | +20.0% |
| Q1 2016 | $1,363,000 | -12.1% | 14,422 | -16.3% | 0.01% | -9.1% |
| Q4 2015 | $1,551,000 | +260.7% | 17,232 | +270.5% | 0.01% | +266.7% |
| Q3 2015 | $430,000 | +14.1% | 4,651 | +21.5% | 0.00% | +50.0% |
| Q2 2015 | $377,000 | +245.9% | 3,828 | +252.2% | 0.00% | +100.0% |
| Q1 2015 | $109,000 | -86.0% | 1,087 | -87.1% | 0.00% | -75.0% |
| Q4 2014 | $776,000 | – | 8,396 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |